Baseline patient characteristics prior to first dose of brentuximab vedotin
| . | N = 25 . |
|---|---|
| Median age, y (range) | 32 (20-56) |
| Male sex, n (%) | 13 (52) |
| ECOG performance status, n (%) | |
| 0 | 9 (36) |
| 1 | 16 (64) |
| Median time from HL diagnosis to first dose of brentuximab vedotin, mo (range) | 72 (19-159) |
| Total number of prior regimens, median (range)* | 9 (5-19) |
| Prior systemic chemotherapy, n (%) | 25 (100) |
| Median no. (range) | 5 (2-12) |
| Prior external beam radiation, n (%) | 22 (88) |
| Prior autoSCT, n (%) | 19 (76) |
| Prior alloSCT, n (%) | 25 (100) |
| Prior DLI, n (%) | 6 (24) |
| . | N = 25 . |
|---|---|
| Median age, y (range) | 32 (20-56) |
| Male sex, n (%) | 13 (52) |
| ECOG performance status, n (%) | |
| 0 | 9 (36) |
| 1 | 16 (64) |
| Median time from HL diagnosis to first dose of brentuximab vedotin, mo (range) | 72 (19-159) |
| Total number of prior regimens, median (range)* | 9 (5-19) |
| Prior systemic chemotherapy, n (%) | 25 (100) |
| Median no. (range) | 5 (2-12) |
| Prior external beam radiation, n (%) | 22 (88) |
| Prior autoSCT, n (%) | 19 (76) |
| Prior alloSCT, n (%) | 25 (100) |
| Prior DLI, n (%) | 6 (24) |
ECOG indicates Eastern Cooperative Oncology Group.
Includes autoSCT, alloSCT, DLI, systemic chemotherapy, and external beam radiation. Conditioning therapy for SCT is not counted as a separate regimen.